大唐药业(836433) - 2024 Q4 - 年度业绩

Financial Performance - The company's operating revenue for 2024 is expected to be CNY 207.45 million, representing a year-on-year increase of 10.20%[5] - The net profit attributable to shareholders is projected to be CNY 94.99 million, a year-on-year growth of 19.82%[5] - The net profit after deducting non-recurring gains and losses is expected to be CNY 13.01 million, reflecting a 37.50% increase compared to the previous year[5] - Basic earnings per share are anticipated to be CNY 0.04, up 33.33% year-on-year[5] Asset and Equity Status - Total assets at the end of the reporting period are estimated to be CNY 662.07 million, a decrease of 10.56% from the beginning of the period[5] - Shareholders' equity attributable to the company is expected to be CNY 477.36 million, down 2.25% from the start of the period[5] Business Strategy and Operations - The company has strengthened marketing management and expanded sales channels, adding over 40 new primary distributors for its product[6] - The increase in net profit is attributed to revenue growth, strict cost control, and an increase in government subsidies recorded as other income[6] - The company has not conducted promotional activities this year, leading to an increase in average product sales prices[6] Financial Caution - The financial data presented is preliminary and has not been audited, cautioning investors about potential risks[7]